GlassScriptPhysician profile
James T Douglas
NPI 1962489732
$5,772.80
in general payments reported to CMS, 2019-2025
41 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $509 · 2021: $1,269 · 2022: $1,395 · 2023: $1,517 · 2024: $288 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933 · Education: $12.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.77 |
| Education | $12.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,533.73 | 2019-2024 | Vraylar, Qulipta, Liletta |
| Pfizer INC. | $593.52 | 2019-2023 | |
| Amgen INC. | $582.16 | 2019-2023 | Tezspire, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $540.34 | 2019-2025 | Tezspire, Airsupra, Evusheld |
| Takeda Pharmaceuticals U.S.A., INC. | $266.99 | 2019-2022 | |
| Lilly USA, LLC | $264.63 | 2019-2024 | Mounjaro, Jardiance |
| Allergan, INC. | $248.32 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.28 | 2019-2023 | |
| Novo Nordisk INC | $115.30 | 2023 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $111.97 | 2022 | |
| Hologic Sales and Service, LLC | $108.47 | 2021-2023 | Coolseal Generator |
| Glaxosmithkline, LLC. | $106.03 | 2019-2023 | Trelegy Ellipta |
| Evofem Biosciences, INC. | $86.11 | 2022-2023 | Phexxi |
| Daiichi Sankyo INC. | $72.74 | 2020-2022 | |
| Cranial Technologies, INC | $72.55 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.